Details for Patent: 7,658,914
✉ Email this page to a colleague
Which drugs does patent 7,658,914 protect, and when does it expire?
Patent 7,658,914 protects MOVIPREP and is included in one NDA.
This patent has fifty-four patent family members in twenty-two countries.
Summary for Patent: 7,658,914
| Title: | Colon cleansing compositions |
| Abstract: | A composition comprising, per liter of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavorings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use. |
| Inventor(s): | Barras; Norman (Chilton, GB), Cox; Ian David (Welton, GB), Ungar; Alex (Cumberland, GB), Halphen; Marc (London, GB) |
| Assignee: | Norgine BV (Amsterdam, NL) |
| Application Number: | 11/636,105 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,658,914 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Device; |
Drugs Protected by US Patent 7,658,914
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Salix Pharms | MOVIPREP | ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate | FOR SOLUTION;ORAL | 021881-001 | Aug 2, 2006 | AA | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,658,914
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0224909.2 | Oct 25, 2002 |
International Family Members for US Patent 7,658,914
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 404223 | ⤷ Sign Up | |||
| Australia | 2003274377 | ⤷ Sign Up | |||
| Australia | 2008100865 | ⤷ Sign Up | |||
| Australia | 2009227838 | ⤷ Sign Up | |||
| Canada | 2502103 | ⤷ Sign Up | |||
| Canada | 2672427 | ⤷ Sign Up | |||
| China | 101897721 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
